How an integrated services model reduces handoffs across development, clinical work, regulatory planning, manufacturing, and biospecimens, and how DCN decides what to build next.
A DCN Dx Expert Insights conversation with Charlie Mamrak, CEO at DCN Dx, hosted by Mitzi Rettinger.
Most IVD programs don’t lose months because a single experiment failed. They lose months at the seams: development to clinical, clinical to regulatory, scale-up to routine manufacturing, and specimen strategy to evidence generation.
In this episode, DCN Dx CEO Charlie Mamrak explains the business decisions behind DCN’s integrated services model, why biospecimens became a priority for IVD developers, and how he evaluates what to build, buy, or collaborate on next. This is a strategy conversation, designed for teams who care about execution, risk, and real-world constraints of diagnostics services companies.
Listen below, or find us on your favorite podcast platform.
What you’ll hear in this episode
- Why integration is the point: what changes when rapid testing CDMO capabilities and IVD clinical research (CRO) services operate as one platform.
- Why biospecimens: what DCN has heard from customers, what offering prospective biospecimens collections changes for IVD developers, and how it fits the broader integration plan for DCN Dx.
- Workforce development as strategy: why DCN teaches the Basic Lateral Flow Course.
- Build vs. buy vs. collaborate: a CEO framework for deciding when new capabilities reduce friction for customers and align to corporate core values vs. simply expanding the menu of services.
Guest
Charlie Mamrak is CEO of DCN Dx. He joined DCN Dx in 2020 after leading multiple diagnostics and life science tools companies, including SeraCare Life Sciences.
